FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092034302> ?p ?o ?g. }

• W2092034302 endingPage "150S" @default.
• W2092034302 startingPage "140S" @default.
• W2092034302 abstract "The reduction in morbidity and mortality associated with thrombolytic therapy in patients with acute myocardial infarction was initially attributed to early restoration of arterial patency, salvage of ischemic myocardium, and preservation of left ventricular function. Recombinant tissue plasminogen activator (rt-PA) was initially the favored thrombolytic agent because of selected studies showing superior early patency rates. Interestingly, averaged results of studies using conventional dosing regimens show 90-min patency rates for streptokinase, rt-PA, and anisoylated plasminogen streptokinase activator complex (APSAC) to be 53%, 68%, and 72%, respectively, suggesting that previous claims exaggerated differences in early patency. More recently, it was found that administering the full 100-mg dose of rt-PA within 90 min increased 90-min patency rates to approximately 85% and that infusing rt-PA plus urokinase or streptokinase halved reocclusion rates. These results again suggest the unrealized potential of rt-PA to offer a unique clinical benefit. However, three important recent trials have challenged the concept that early patency conveys a survival benefit by showing no difference in mortality in patients treated with different thrombolytic agents. Other trials have shown survival benefit in patients in whom patency of the infarct artery was achieved in a time frame beyond that in which myocardial salvage could be expected. The “open-artery hypothesis” suggests that survival may be more dependent on improved left ventricular remodeling and healing, increased electrical stability, and better myocardial perfusion than on infarct size reduction. In an attempt to determine whether 90-min patency or 24-h patency is more predictive of survival, the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial will randomize approximately 40,000 patients to (1) streptokinase and subcutaneous heparin; (2) streptokinase and intravenous heparin; (3) front-loaded, weight-adjusted rt-PA and intravenous heparin; or (4) the combination of streptokinase and rt-PA and intravenous heparin. The reduction in morbidity and mortality associated with thrombolytic therapy in patients with acute myocardial infarction was initially attributed to early restoration of arterial patency, salvage of ischemic myocardium, and preservation of left ventricular function. Recombinant tissue plasminogen activator (rt-PA) was initially the favored thrombolytic agent because of selected studies showing superior early patency rates. Interestingly, averaged results of studies using conventional dosing regimens show 90-min patency rates for streptokinase, rt-PA, and anisoylated plasminogen streptokinase activator complex (APSAC) to be 53%, 68%, and 72%, respectively, suggesting that previous claims exaggerated differences in early patency. More recently, it was found that administering the full 100-mg dose of rt-PA within 90 min increased 90-min patency rates to approximately 85% and that infusing rt-PA plus urokinase or streptokinase halved reocclusion rates. These results again suggest the unrealized potential of rt-PA to offer a unique clinical benefit. However, three important recent trials have challenged the concept that early patency conveys a survival benefit by showing no difference in mortality in patients treated with different thrombolytic agents. Other trials have shown survival benefit in patients in whom patency of the infarct artery was achieved in a time frame beyond that in which myocardial salvage could be expected. The “open-artery hypothesis” suggests that survival may be more dependent on improved left ventricular remodeling and healing, increased electrical stability, and better myocardial perfusion than on infarct size reduction. In an attempt to determine whether 90-min patency or 24-h patency is more predictive of survival, the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial will randomize approximately 40,000 patients to (1) streptokinase and subcutaneous heparin; (2) streptokinase and intravenous heparin; (3) front-loaded, weight-adjusted rt-PA and intravenous heparin; or (4) the combination of streptokinase and rt-PA and intravenous heparin." @default.
• W2092034302 created "2016-06-24" @default.
• W2092034302 creator A5012372560 @default.
• W2092034302 date "1992-04-01" @default.
• W2092034302 modified "2023-09-25" @default.
• W2092034302 title "Is Survival in Acute Myocardial Infarction Related to Thrombolytic Efficacy or the Open-Artery Hypothesis?" @default.
• W2092034302 cites W1497401590 @default.
• W2092034302 cites W1533600198 @default.
• W2092034302 cites W1920261218 @default.
• W2092034302 cites W1924409040 @default.
• W2092034302 cites W1963983782 @default.
• W2092034302 cites W1964493111 @default.
• W2092034302 cites W1970888273 @default.
• W2092034302 cites W1971494714 @default.
• W2092034302 cites W1972640155 @default.
• W2092034302 cites W1977967610 @default.
• W2092034302 cites W1981567532 @default.
• W2092034302 cites W1984101828 @default.
• W2092034302 cites W1984670333 @default.
• W2092034302 cites W1985452790 @default.
• W2092034302 cites W1986401369 @default.
• W2092034302 cites W1991747655 @default.
• W2092034302 cites W1992085813 @default.
• W2092034302 cites W1994313737 @default.
• W2092034302 cites W1994336882 @default.
• W2092034302 cites W1995664259 @default.
• W2092034302 cites W1996794420 @default.
• W2092034302 cites W1999412043 @default.
• W2092034302 cites W2000700283 @default.
• W2092034302 cites W2002211405 @default.
• W2092034302 cites W2003818257 @default.
• W2092034302 cites W2004941049 @default.
• W2092034302 cites W2006412880 @default.
• W2092034302 cites W2007444768 @default.
• W2092034302 cites W2012572923 @default.
• W2092034302 cites W2017731963 @default.
• W2092034302 cites W2021692378 @default.
• W2092034302 cites W2021856113 @default.
• W2092034302 cites W2022138186 @default.
• W2092034302 cites W2024779567 @default.
• W2092034302 cites W2030775477 @default.
• W2092034302 cites W2035389716 @default.
• W2092034302 cites W2036004307 @default.
• W2092034302 cites W2038391832 @default.
• W2092034302 cites W2040675937 @default.
• W2092034302 cites W2041897542 @default.
• W2092034302 cites W2042476232 @default.
• W2092034302 cites W2044191826 @default.
• W2092034302 cites W2044722146 @default.
• W2092034302 cites W2046312368 @default.
• W2092034302 cites W2046903335 @default.
• W2092034302 cites W2050928004 @default.
• W2092034302 cites W2052892416 @default.
• W2092034302 cites W2053345731 @default.
• W2092034302 cites W2053942123 @default.
• W2092034302 cites W2055992885 @default.
• W2092034302 cites W2056684124 @default.
• W2092034302 cites W2062539394 @default.
• W2092034302 cites W2064261225 @default.
• W2092034302 cites W2064632534 @default.
• W2092034302 cites W2065251676 @default.
• W2092034302 cites W2069054602 @default.
• W2092034302 cites W2069302320 @default.
• W2092034302 cites W2077806955 @default.
• W2092034302 cites W2078635736 @default.
• W2092034302 cites W2079684578 @default.
• W2092034302 cites W2081979723 @default.
• W2092034302 cites W2083383568 @default.
• W2092034302 cites W2084852338 @default.
• W2092034302 cites W2088770941 @default.
• W2092034302 cites W2089847188 @default.
• W2092034302 cites W2089872780 @default.
• W2092034302 cites W2090372899 @default.
• W2092034302 cites W2093790861 @default.
• W2092034302 cites W2095482249 @default.
• W2092034302 cites W2111386086 @default.
• W2092034302 cites W2112911632 @default.
• W2092034302 cites W2114742226 @default.
• W2092034302 cites W2135544883 @default.
• W2092034302 cites W2143667702 @default.
• W2092034302 cites W2157466144 @default.
• W2092034302 cites W2322228296 @default.
• W2092034302 cites W2336267479 @default.
• W2092034302 cites W2340168757 @default.
• W2092034302 cites W3170680033 @default.
• W2092034302 cites W4243224266 @default.
• W2092034302 cites W4245105995 @default.
• W2092034302 doi "https://doi.org/10.1378/chest.101.4_supplement.140s" @default.
• W2092034302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1555479" @default.
• W2092034302 hasPublicationYear "1992" @default.
• W2092034302 type Work @default.
• W2092034302 sameAs 2092034302 @default.
• W2092034302 citedByCount "3" @default.
• W2092034302 crossrefType "journal-article" @default.
• W2092034302 hasAuthorship W2092034302A5012372560 @default.
• W2092034302 hasConcept C126322002 @default.
• W2092034302 hasConcept C146957229 @default.
• W2092034302 hasConcept C164705383 @default.

• next